Viatris (VTRS) has been back in focus after quarterly revenue and earnings topped analyst estimates, management reaffirmed full year guidance, and investors heard fresh updates on cost savings and the drug pipeline.

The share price reaction has been strong, with a 9.03% 1 day share price return and a 32.14% 30 day share price return. In addition, the 1 year total shareholder return of 100.23% signals powerful momentum that has built over time.

If Viatris has sharpened your interest in healthcare, it could be worth scanning for other potential opportunities using our focused list of 35 healthcare AI stocks

After a 100.23% 1 year total return, Viatris is no longer flying under the radar. With the share price now above the average analyst target yet screens flagging a large intrinsic discount, some investors may be asking whether this is still a buying opportunity or if the market is already pricing in future growth.

Most Popular Narrative: 55.7% Undervalued

Against the last close of $17.39, the most followed narrative pegs Viatris' fair value at $39.24, a much higher anchor point for debate.

The early years were tough: many Upjohn products were in natural decline, the generics market is brutally competitive, and the merger came with a heavy debt load. Investors saw a company that needed to shrink rather than grow, and the stock lagged for years.

Want to see what kind of revenue path and profit margin reset has to play out to support that price, and why the narrative leans on a richer future earnings multiple?

Result: Fair Value of $39.24 (UNDERVALUED)

However, this hinges on execution. Weaker cash generation, slower progress on debt, or pressure on key products could quickly challenge that 55.7% undervalued narrative.

Next Steps

With sentiment split between risks and rewards, this is a moment to move quickly, review the data for yourself, and weigh up the 3 key rewards and 1 important warning sign

Looking for more investment ideas?

Do not stop with one stock story; broaden your watchlist now so you can compare quality, risk, and income potential across very different types of opportunities.

• Target income resilience by reviewing companies in the 12 dividend fortresses and see which stocks currently offer higher yields with supporting fundamentals.
• Spot potential mispricings early by scanning the 51 high quality undervalued stocks so you can quickly compare valuations with balance sheet strength and cash generation.
• Sleep easier at night by focusing on businesses in the 72 resilient stocks with low risk scores and reduce the chance that one position dominates your portfolio risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.